Even though other mitotic checkpoint targeted therapies have achieved complete tumor regressions (e.g. CENP-E inhibitors [31]), no Mps1 inhibitor has produced profound efficacy in the absence of confounding toxicities. This evidence concerns the gene TTK and neoplasm.